The success of Theranos, the blood-testing startup recently valued at $10 billion, has inspired many other health-care startups in recent years. Now, in the wake of reports that question the accuracy and effectiveness of its technology, the company is serving as a cautionary tale of what happens when Silicon Valley's disruptive ethos clashes with regulated sectors of the economy.